1. Detection of Candida albicans in the peripheral blood smear of a diffuse large B cell lymphoma patient

   • Shoya Arai
   • Takeshi Osawa
   • Haruko Tashiro

   Images in Hematology 25 January 2023 Pages: 309 - 310

   

2. Inclusion of thymic Langerhans cell histiocytosis in the “5 Ts” of the differential diagnosis of anterior mediastinal mass

   • Kenichi Sakamoto
   • Kentaro Fujimori
   • Yoko Shioda

   Images in Hematology 04 February 2023 Pages: 311 - 313

   

3. Progress in pathophysiological understanding and treatment of thrombocytopenia

   • Hirokazu Kashiwagi

   Progress in Hematology 19 January 2023 Pages: 314 - 315

4. Recent progress in ITP treatment

   • Francesco Rodeghiero

   Progress in Hematology 09 January 2023 Pages: 316 - 330

   

5. Frontiers in pathophysiology and management of thrombotic thrombocytopenic purpura

   • Masayuki Kubo
   • Masanori Matsumoto

   Progress in Hematology 09 February 2023 Pages: 331 - 340

   

6. Unique features of vaccine-induced immune thrombotic thrombocytopenia; a new anti-platelet factor 4 antibody-mediated disorder

   • Laura M. Venier
   • Bianca Clerici
   • Donald M. Arnold

   Progress in Hematology 27 December 2022 Pages: 341 - 348

7. Ex vivo manufacturing of platelets: beyond the first-in-human clinical trial using autologous iPSC-platelets

   • Si Jing Chen
   • Naoshi Sugimoto
   • Koji Eto

   Progress in Hematology 27 December 2022 Pages: 349 - 355

   

8. Outcome of peripheral blood stem cell transplantation from HLA-identical sibling donors for adult patients with aplastic anemia

   • Yukinori Nakamura
   • Takehiko Mori
   • Yasushi Onishi

   Original Article 15 November 2022 Pages: 356 - 365

   

9. The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study

   • Yoshitaka Miyakawa
   • Kazunori Imada
   • Masanori Matsumoto

   Original Article Open access 24 November 2022 Pages: 366 - 377

   

10. Real-world bleeding outcomes and product utilization in people with severe-type hemophilia A before and after switching to extended half-life rFVIIIFc prophylaxis therapy

    • Chia-Yau Chang
    • Shiue-Wei Lai
    • Yeu-Chin Chen

    Original Article 04 December 2022 Pages: 378 - 387

    

11. Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies

    • Ana C. Oliveira
    • Josep Maria Roncero
    • Eva González-Barca

    Original Article 30 November 2022 Pages: 388 - 397

    

12. Age and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia

    • Masamitsu Yanada
    • Satoshi Yamasaki
    • Shingo Yano

    Original Article 06 November 2022 Pages: 398 - 408

    

13. A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis

    • Koji Kato
    • Nobuharu Fujii
    • Kiyohiko Hatake

    Original Article 18 November 2022 Pages: 409 - 420

    

14. Severe short-term adverse events in related bone marrow or peripheral blood stem cell donors

    • Ryu Yanagisawa
    • Tsuneaki Hirakawa
    • Nobuhiro Tsukada

    Original Article 20 November 2022 Pages: 421 - 427

    

15. Cryopreserved versus fresh peripheral blood allogeneic stem cell transplantation outcomes in patients receiving post-transplant cyclophosphamide for graft-versus-host prophylaxis during the COVID-19 pandemic: a single center experience

    • Mengni Guo
    • Jieying Liu
    • Shahram Mori

    Original Article 15 November 2022 Pages: 428 - 437

    

16. Endothelial function testing before conditioning therapy is useful for predicting transplant-related complications after allogeneic hematopoietic cell transplantation

    • Shojiro Haji
    • Motoaki Shiratsuchi
    • Yoshihiro Ogawa

    Original Article 27 November 2022 Pages: 438 - 445

    

17. Current childhood chronic myeloid leukemia management under tyrosine kinase inhibitor treatment

    • Nihal Karadaş
    • Şerife Şebnem Önen Göktepe
    • Deniz Yilmaz Karapinar

    Original Article 19 November 2022 Pages: 446 - 455

    

18. Chronic myeloid leukemia (CML) evolves from Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs) with unexpected frequency

    • Michael J. Hochman
    • B. Douglas Smith
    • Amy E. DeZern

    Case Report 01 October 2022 Pages: 456 - 462

    

19. Daratumumab plus lenalidomide and dexamethasone for relapsed POEMS syndrome with bone plasmacytoma harboring 17p deletion

    • Takashi Oyama
    • Kazuki Taoka
    • Mineo Kurokawa

    Case Report 06 October 2022 Pages: 463 - 467

    

20. Correction to: Refined ultrasonographic criteria for sinusoidal obstruction syndrome after hematopoietic stem cell transplantation

    • Mutsumi Nishida
    • Junichi Sugita
    • Takanori Teshima

    Correction 17 February 2023 Pages: 468 - 468

21. Correction: Efficacy and safety of equine anti-thymocyte immunoglobulin (eATG) in three Japanese patients with moderate to very severe aplastic anemia: a case series

    • Yoshinobu Kanda
    • Takehiko Mori
    • Kazuma Nishimura

    Correction Open access 25 January 2023 Pages: 469 - 469